Cancer Treatment in China: Advanced Oncology Care with Multidisciplinary Evaluation
We connect international patients with solid tumors and blood cancers to leading public Class-A tertiary cancer centers and national regional medical centers across China — providing rigorous, transparent treatment feasibility assessments, multidisciplinary team (MDT) care planning, and coordination of advanced clinical therapies.
Clinically trained bilingual translators standardize your progress notes, pathology and imaging reports so Class-A tertiary specialists can review them without delay.
Case review is strictly handled by senior attending experts at top public institutions including the National Cancer Center of China, Sun Yat-sen University Cancer Center (SYSUCC) and Fudan University Shanghai Cancer Center.
The platform charges one flat USD 300 fee for initial record review and foreign-affairs coordination. All hospital medical expenses are settled by you directly at the public hospital — no intermediary markup of any kind.
All assessments strictly follow Chinese Society of Clinical Oncology (CSCO) and international NCCN guidelines. We will not recommend intake without a clear clinical indication or for end-stage cases — staying firmly within medical ethics.
Which Cancer Patients Should Submit Their Case — and When Is the Right Time?
Cross-border care demands significant time and effort from patients and their families. We therefore recommend starting a case review only for cancer patients with a clear, realistic expectation of clinical benefit.
Newly Diagnosed and Needing a Multidisciplinary (MDT) Treatment Plan
Your pathology is confirmed, but the right sequence — upfront surgery, neoadjuvant chemotherapy to shrink the tumor, or concurrent chemoradiotherapy — is being debated. You need a joint consultation across surgery, medical oncology and radiation oncology at an authoritative public Class-A tertiary cancer hospital to lock in a curative path.
Advanced or Relapsed-Refractory Cancer Seeking Innovative Therapies
After resistance to first- or second-line conventional chemotherapy in your home country, you want to explore China-approved options such as CAR-T cell immunotherapy, antibody-drug conjugates (ADCs), bispecific antibodies, or the newest mutation-targeted combinations (e.g., KRAS, RET and HER2 mutations).
Locally Complex Tumors Needing High-Precision Radiotherapy Assessment
The primary or metastatic tumor sits close to critical structures — major nerves and vessels, skull base, brainstem, spinal cord or heart — where conventional photon radiation would carry unacceptable side effects. You want a professional evaluation of proton & heavy-ion therapy or stereotactic body radiation therapy (SBRT).
Cross-Border Pathology & Molecular Subtyping Second Opinion
Slides reviewed at an overseas facility show an uncertain or suspicious subtype. A national-level pathology quality-control center can re-verify the diagnosis with immunohistochemistry (IHC) or deep next-generation sequencing (NGS), correcting potential misclassification and precisely guiding subsequent targeted therapy.
Why Do Global Patients Choose China for the Best Cancer Treatment?
Backed by enormous real-world clinical volume, world-leading biopharmaceutical innovation and a fast-growing proton therapy network, China has become a high-value destination for international cancer care — strong outcomes at a fraction of the cost.
Breadth of Clinical & Surgical Experience
China's top public Class-A tertiary cancer centers — such as the Cancer Hospital, Chinese Academy of Medical Sciences and Sun Yat-sen University Cancer Center (SYSUCC) — rank among the world's highest in annual outpatient volume and surgical caseload. For demanding procedures like sphincter-preserving ultra-low rectal cancer resection, complex pancreatic cancer surgery and giant mediastinal masses, their surgical teams deliver precision and complication control at an extremely high global standard.
Access to Innovative Drugs & Therapies
China has developed more than a dozen domestically approved PD-1/PD-L1 immune checkpoint inhibitors. Novel ADCs (antibody-drug conjugates) for EGFR rare mutations, MET exon 14 skipping and HER2 mutations — as well as CAR-T cell therapies — are approved in step with global markets, with ample clinical supply and very short waiting times for patients.
Cutting-Edge Radiotherapy Equipment Base
Chinese Class-A tertiary cancer centers are widely equipped with leading-brand linear accelerators and stereotactic radiotherapy systems. Mature proton programs — including Shanghai Proton and Heavy Ion Center and Shandong Cancer Hospital's proton center — treat hundreds of complex solid-tumor patients each year, with sub-millimeter accuracy in target delineation.
Transparent, Globally Competitive Costs
Unlike the high out-of-pocket bills of Western or private hospitals, public Class-A tertiary hospitals in China charge strictly according to government-approved pricing schedules — bed fees, routine chemotherapy and surgery costs are fully disclosed. Domestically developed PD-1 inhibitors and targeted drugs typically cost one-fifth to one-tenth of comparable overseas originals, greatly reducing the financial burden on international patients.
Core Cancer Records & Imaging Checklist to Prepare
To help public Class-A tertiary cancer experts reach definitive, clinically actionable conclusions during pre-review and consultation, please prepare your original medical documents according to this standardized checklist:
Pathology Diagnosis Report
Biopsy or prior surgical pathology slides and reports, including complete immunohistochemistry (IHC) markers such as HER2, ER/PR, Ki-67 and PD-L1 TPS/CPS scores.
Format: PDF scan or clear full-page photoOriginal Imaging Data Within 30 Days (DICOM)
Original disc data of contrast-enhanced CT (chest/abdomen/pelvis), contrast-enhanced MRI, whole-body PET-CT or bone scans. Specialists need the raw files to re-measure lesions at their own window settings — paper reports alone are not sufficient.
Format: DICOM original archive (ZIP/RAR)Genomic Testing Report (NGS)
If high-throughput next-generation sequencing was performed, provide the complete report — including EGFR, ALK, ROS1, KRAS, BRAF, RET, MET and BRCA1/2 alterations, plus TMB/MSI status.
Format: original PDF sequencing analysis reportHistory of Prior Systemic Treatment & Medications
Names of prior chemotherapy drugs with cycle counts and doses; radiotherapy total dose and irradiated target fields; exact start/stop dates of any prior targeted or immunotherapy, plus the time point of progression or resistance.
Format: prior discharge summaries or prescription recordsRecent Performance Status & Baseline Lab Tests
The patient's self-care ability within the past week (ECOG performance status 0-4), plus complete blood count, liver and kidney function, coagulation and ECG results from the last 7 days — used to judge whether the patient can tolerate long international travel.
Format: copies or photos of routine lab reportsA DICOM disc usually contains thousands of image files (1-5 GB). You don't need to send them one by one over WeChat: the platform provides a dedicated high-bandwidth international upload channel for very large files, and coordinators can also help you extract them.
Cancer Treatment Options by Sub-Specialty: Finding the Right Center in China
Each sub-specialty runs a chief-expert system for single disease entities, matching every tumor type's biology to the most suitable public Class-A tertiary center.
Lung Cancer Comprehensive Care Center
Covers non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): next-generation targeted therapy for common EGFR/ALK mutations and rare drivers such as KRAS G12C, RET, MET and HER2, plus preoperative neoadjuvant chemo-immunotherapy and concurrent chemoradiotherapy for locally advanced disease.
Breast Cancer Precision Care Center
Covers triple-negative breast cancer (TNBC), HER2-positive and HR-positive breast cancer. Key evaluations include novel antibody-drug conjugates (ADCs such as trastuzumab deruxtecan, already maturely available in China), precision breast-conserving oncoplastic surgery and combination regimens for endocrine resistance.
Gastrointestinal (GI) Oncology Center
Gastric cancer, colorectal cancer, primary liver cancer and pancreatic cancer. Building on China's exceptionally rich GI surgical caseload, the center performs laparoscopic/robotic ultra-minimally invasive curative resections, transarterial chemoembolization (TACE) combined with targeted-immunotherapy for liver cancer, and HIPEC comprehensive therapy for peritoneal metastasis.
Blood Cancers & CAR-T Cell Therapy
Focused on relapsed/refractory diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and acute lymphoblastic leukemia (ALL). China sits in the world's leading tier for CAR-T clinical research and commercial products targeting CD19 and BCMA.
Prostate Cancer & Urologic Oncology
Metastatic castration-resistant prostate cancer (mCRPC), renal cell carcinoma and bladder urothelial carcinoma. The center applies robotic nerve-sparing radical prostatectomy, novel androgen receptor inhibitors and precision radionuclide therapy.
Proton & Heavy-Ion High-Precision Radiotherapy
Using the "Bragg Peak" physics of proton and heavy-ion beams, radiation energy is deposited precisely deep inside the tumor target with near-zero dose to surrounding healthy tissue. Especially suitable for skull-base chordoma and chondrosarcoma, pediatric malignant solid tumors and early-stage lung cancer.
What Drives the Cost of Cancer Treatment in China — and How Charging Stays Compliant
Why can a reputable Class-A tertiary hospital never quote a misleading flat "one price for everything" for cancer? Cancer treatment is a highly individualized, dynamic clinical process, and the total cost is directly shaped by multiple clinical variables:
A single curative minimally invasive resection for early solid tumors has relatively predictable costs. In advanced disease with multiple metastases requiring sequential lines of therapy, whether sensitive driver mutations are detected decides the drug pathway — and the cost trajectory.
Chemotherapy alone versus chemotherapy plus immunotherapy versus proton radiotherapy combined with targeted therapy — the technologies involved (robotic surgical consumables, proton beam time) differ greatly in cost.
Imported originator drugs, biosimilars and China-developed PD-1 antibodies sit at clearly different price points. Under the guidance of your attending physician, you can also choose an equally effective, more affordable regimen to fit your budget.
Individual recovery variables — severe chemotherapy-induced myelosuppression requiring growth factors or blood transfusions, or intensive care unit (ICU) monitoring after surgery — all affect the final hospital settlement.
MedTravel China Charges One Flat USD 300 Medical Coordination Fee
We maintain a clean, strictly neutral coordination model: the USD 300 covers bilingual medical record organization and translation, acceptance assessment by Class-A tertiary specialists, and assistance with your medical visa application. All chemotherapy, targeted drugs, surgery and radiotherapy are paid by you in person with your passport at the official billing counter of the public Class-A tertiary hospital — the platform never touches any medical payment.
Frequently Asked Questions About Cancer Treatment in China
The process, cost and clinical feasibility questions international cancer patients ask most before traveling
Ready to Submit Your Cancer Case and Get an Authoritative Assessment from Chinese Specialists?
Upload your complete pathology and imaging reports. A senior bilingual medical coordination manager will complete the initial document review and clinical-validity check within 24 hours, then arrange the next step of specialist matching at a Class-A tertiary hospital.
info Medical information on this site is for general reference only and does not constitute medical advice, diagnosis, or treatment recommendations. Actual care decisions rest with the licensed physicians of the hospital.